The Latest Breaking News from Lilly

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking them, figures from the UK’s medicines regulator reveal

Exclusive: Julie Bishop lost two-and-a-half stone in eight weeks by taking Mounjaro before she was sent to hospital with pancreatitis and told to stop taking the weight-loss jab

UK health officials launch study into side-effects of weight loss drugs after increased reports of acute pancreatitis